HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry: A study of interlaboratory agreement

American Journal of Clinical Pathology

Volumn 113, Issue 2, 2000, Pages 251-258

  Jacobs, Timothy W ^a   Gown, Allen M ^b   Yaziji, Hadi ^b   Barnes, Melissa J ^a   Schnitt, Stuart J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PHENOPATH LABORATORIES   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; c erbB 2; HER 2 neu; Immunohistochemistry

Indexed keywords

ADULT; AGED; ANTIGEN RETRIEVAL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY AUTOMATION; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STANDARDIZATION; TISSUE SECTION;

EID: 0033996013     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/980m-e24r-v19k-595d     Document Type: Article

References (70)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
3. Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7:1120-1128.
4. Thor AD, Schwartz LH, Koerner FC, et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res. 1989;49:7147-7152.
5. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49:2087-2090.
6. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332-4337.
7. Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer [published correction appears in Br J Cancer. 1991;64:202]. Br J Cancer. 1991;63:439-443.
8. O'Reilly SM, Barnes DM, Camplejohn RS, et al. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer. 1991;63:444-446.
9. McCann AH, Dervan PA, O'Regan M, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res. 1991;51:3296-3303.
10. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49: 650-655.
11. Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49:44-49.
12. Anbazhagan R, Gelber RD, Bettelheim R, et al. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol. 1991;2:47-53.
13. Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991;63:447-450.
14. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992:10:1049-1056.
15. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992;10:1044-1048.
16. Tiwari RK, Borgen PI, Wong GY, et al. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 1992;12:419-425.
17. Noguchi M, Koyasaki N, Ohta N, et al. C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer. 1992;69:2953-2960.
18. Gasparini G, Gullick WJ, Bevilacqua P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol. 1992;10:686-695.
19. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol. 1993;11:1936-1942.
20. Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: results from a randomized adjuvant treatment protocol. Cancer. 1994;74:2956-2963.
21. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer. 1994;73:2359-2365.
22. Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 1995;35:283-291.
23. Ro JS, el-Naggar A, Ro JY, et al. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res. 1989;49:6941-6944.
24. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103-112.
25. Dykins R, Corbett IP, Henry JA, et al. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol. 1991;163:105-110.
26. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960-4970.
27. Giai M, Roagna R, Ponzone R, et al. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res. 1994;14:1441-1450.
28. O'Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum Pathol. 1996;27:955-963.
29. Albanell J, Bellmunt J, Molina R, et al. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res. 1996;16:1027-1032.
30. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-2904.
31. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group. J Clin Oncol. 1998;16:1340-1349.
32. Ross JS, Muraca PJ, Jaffe D, et al. Multivariate analysis of prognostic factors in lymph node negative breast cancer [abstract]. Mod Pathol. 1998;11:26A.
33. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991;51:944-948.
34. Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:556-567.
35. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599-605.
36. Bianchi S, Paglierani M, Zampi G, et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer. 1993;67:625-629.
37. Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer. 1995;75:1320-1326.
38. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc ASCO. 1998;17:97A.
39. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc ASCO. 1998;17:98A.
40. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659-2671.
41. Stal O, Sullivan S, Wingren S, et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 1995;31A:2185-2190.
42. Bitran JD, Samuels B, Trujillo Y, et al. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast caneer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res. 1996;2:1509-1513.
43. Tetu B, Brisson J, Plante V, et al. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol. 1998;11:823-830.
44. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
45. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
46. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361-1370.
47. Ravdin PM, Green S, Albain KS, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with Tamoxifen (T) alone [abstract]. Proc ASCO. 1998;17:97A.
48. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65:118-121.
49. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 1994;81:137-144.
50. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702-2708.
51. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462-469.
52. Lundy J, Schuss A, Stanick D, et al. Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer: correlation with clinicopathologic parameters. Am J Pathol. 1991;138:1527-1534.
53. Singleton TP, Niehans GA, Gu F, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol. 1992;23:1141-1150.
54. Kerns BJ, Jordan PA, Huper G, et al. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod Pathol. 1993;6:673-678.
55. Bobrow LG, Happerfield LC, Millis RR. Comparison of immunohistological staining with different antibodies to the c-erbB-2 oncoprotein. Appl Immunohistochemistry. 1996;4:128-134.
56. Heatley M, Maxwell P, Whiteside C, et al. C-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human hreast carcinoma. Pathol Res Pract. 1993;189:261-266.
57. Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human hreast cancer: impact of fixation. J Pathol. 1994;173:65-75.
58. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
59. Kay EW, Walsh CJ, Cassidy M, et al. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol. 1994;47:816-822.
60. Busmanis I, Feleppa F, Jones A, et al. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. Pathology. 1994;26:261-267.
61. Ross JS, Fletcher JA. The HER-2/neu oncoprotein in hreast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3:237-252.
62. Clark GM. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status [editorial]? J Natl Cancer Inst. 1998;90:1320-1321.
63. Solomides CC, Zimmerman R, Bibbo M. Semiquantitative assessment of c-erbB-2 (HER-2) status of cytology specimens and tissue sections from breast carcinoma. Anal Quant Cytol Histol. 1999;21:121-125.
64. Graziano C. HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Today. 1998;12:13-16.
65. Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody [letter]. J Clin Oncol. 1999;17:434.
66. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987.
67. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
68. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia, PA: Lippincott-Raven; 1996:461-485.
69. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer J Clin Oncol. 1999;17:1974-1982.
70. Haerslev T, Jacobsen GK. Microwave processing of formalin-fixed and paraffin-embedded sections improves the immunoreactivity of c-erbB-2 oncoprotein in breast carcinoma. Appl Immunohistochem. 1993;1:223-226.